Charles Watson Moore

Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

Alan J. Kraker, Brian G. Hartl, Aneesa M. Amar et al. · Biochemical Pharmacology · 2000 · 139 citations · Full text

Medicine, Molecular Biology, Pharmacology +12

Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

A J Kraker, Charles Watson Moore · PubMed · 1988 · 121 citations

Medicine, Oncology, Pharmacology +13

Tyrosine Kinase Inhibitors. 6. Structure−Activity Relationships among <i>N</i>- and 3-Substituted 2,2‘-Diselenobis(1<i>H</i>-indoles) for Inhibition of Protein Tyrosine Kinases and Comparative <i>in Vitro</i> and <i>in Vivo</i> Studies against Selected Sulfur Congeners

H. D. Hollis Showalter, Anthony D. Sercel, Boguslawa Leja et al. · Journal of Medicinal Chemistry · 1997 · 64 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Structure–activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1

Brian D. Palmer, Jeff B. Smaill, Gordon W. Rewcastle et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 60 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Soluble 2-Substituted Aminopyrido[2,3-<i>d</i>]pyrimidin-7-yl Ureas. Structure−Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity

Mel C. Schroeder, James M. Hamby, Cleo J. C. Connolly et al. · Journal of Medicinal Chemistry · 2001 · 53 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15